COMMUNIQUÉS West-GlobeNewswire

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
22/10/2026
Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027 MELBOURNE, Australia, Oct. 22, 2026 ( [...]
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
22/10/2026
VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call
22/10/2026
SAN CLEMENTE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter [...]
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
22/10/2026
- MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology - - In Korea, only about one in [...]
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
22/10/2026
BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report [...]
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
22/10/2026
Company to host conference call on November 5, 2026, at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company [...]
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
22/10/2026
WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today [...]
BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness
22/10/2026
BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine. New York, Oct. 22, [...]
Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
22/10/2026
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation Discussion features Sanjeev Luther, President and Chief [...]
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
22/10/2026
TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage [...]
Promaxo Announces Closing of Series C Financing and $100M Credit Facility
22/10/2026
The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings OAKLAND, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Promaxo today announced the initial close of its Series C [...]
Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy
22/10/2026
Submission marks an important milestone towards bringing a new treatment option to patients with DMD in South Korea. Vamorolone has already received South Korean Orphan Drug Designation (ODD) and Global Innovative [...]
Levicept Announces Attendance at Major Healthcare Conferences in Q4
22/10/2026
SANDWICH, United Kingdom, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a clinical-stage biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), is pleased to [...]
KFSH Expands Capacity for Complex Care by Redesigning the Emergency Patient Journey
22/10/2026
RIYADH, Saudi Arabia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has expanded capacity for complex care by redesigning the emergency patient journey, meeting rising [...]
Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection
22/10/2026
kt-5000AI delivers potent and selective ATR inhibition, CNS-oriented properties and preclinical tumour-growth control, advancing a capital-efficient drug discovery program toward candidate selection VANCOUVER, British [...]
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
22/10/2026
PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, [...]
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026
22/10/2026
LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30 [...]
Une nouvelle étude sur EggNest® publiée dans JAHA et une dérogation réglementaire au Texas confirment l’évolution vers des procédures sans tablier plombé en salle de cardiologie interventionnelle
22/10/2026
MINNEAPOLIS, 22 oct. 2026 (GLOBE NEWSWIRE) -- Egg Medical a annoncé aujourd’hui la publication d’une étude prospective dans le Journal of the American Heart Association (JAHA), évaluant ses dispositifs renforcés de [...]
argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
22/10/2026
Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for submission [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum